Thermo Fisher Scientific Inc., the world leader in serving science, has unveiled the Gibco™ Efficient-Pro™ Medium (+) Insulin, a next-generation medium designed to increase titers to maximise productivity and elevate the performance of insulin-dependent CHO cell lines.
Efficient-Pro Medium (+) Insulin is the latest addition to Thermo Fisher’s existing Efficient-Pro medium and feed system, designed to provide optimized growth and productivity for insulin-dependent CHO cell lines, with streamlined workflow and handling.
Efficient-Pro Medium (+) Insulin offers improved protein yield and optimised productivity for insulin-dependent CHO cell lines commonly used in monoclonal antibody and biosimilar production, while also simplifying the preparation process and logistics.
For protein therapeutic developers (e.g., mAb, bispecific, Fc-fusion proteins, etc.), Efficient-Pro Medium (+) Insulin simplifies process development by providing consistent, high-performance growth and production conditions with reduced variability.
As the biologics industry pushes for faster development timelines, reduced cost-of-goods, and greater supply chain agility, Efficient-Pro Medium (+) Insulin provides a future-ready solution. It is designed to eliminate the need for manual insulin supplementation, and for robust quality systems that help support supply assurance and confidence in the delivery of consistent, high-quality products — further simplifying the bioproduction process for customers.
